A Histopathological, Immunohistochemical and Biochemical Investigation on the in vitro Antioxidant, Myeloprotective, Hematoprotective and Hepatoprotective Effects of Hypericum triquetrifolium Seed Extract Against Cyclophosphamide-Induced Toxicity

Abstract The aim of this study was to investigate in vitro antioxidant properties and in vivo protective effects of the methanol extract of the Hypericum triquetrifolium Turra (HT) seed against acute hepatotoxicity, myelotoxicity and hematotoxicity in rats induced by cyclophosphamide (CP). In order to investigate in vivo protective effects of the HT extract on rat tissues, the rats were divided into nine groups. The toxic effects of CP and the protective effects of HT extract on nucleated cells that are produced by bone marrow, serum alanine transaminase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and oxidative stress index (OSI) levels were investigated biochemically. Additionally, liver tissue samples were examined for histopathological changes and apoptosis by Bcl-2, Bax and caspase-3 immunohistochemistry. The results of this study show that HT seed methanol extract has high total phenolic content (179.52 μg GAE/mg) and antioxidant activity (87.48% in 500 μg/mL concentration). CP administration caused hepatotoxicity, myelotoxicity and hematotoxicity in the rats. Whereas, the groups of rats that were injected with different concentrations of HT (25, 50 and 100 mg/kg) and CP (150 mg/kg) showed significant protective effects on bone marrow nucleated cells and important decreases on serum ALT, ALP, LDH and OSI levels were observed when compared with the CP injected group.

Combined protective effect of zinc oxide nanoparticles and melatonin on cyclophosphamide-induced toxicity in testicular histology and sperm parameters in adult Wistar rats

Background: Cyclophosphamide [CP] has been known as an anticancer drug with several side effects on various organs such as a male reproductive system that can cause infertility

Objective: To evaluate the possible combined effects of zinc oxide nanoparticles [nZno] and melatonin [Mel] on sperm parameters and histopathological changes of the testis in CP-treated rats

Materials and Methods: 42 adult male Wistar rats were divided into six groups. GI: control, GII: 60 mg/kg/wk CP, GIII and GIV, 10 mg/kg/wk Mel and 5mg/kg/wk nZno and GV: 5 mg/kg/wk nZno and 10 mg/kg/wk Mel were given 2 hr prior to CP injection, respectively, GVI: 5mg/kg/wk nZno and 10 mg/kg/wk Mel simultaneously. After 8 wk of treatment, rats were sacrificed and testis and epididymis were harvested for further evaluation

Results: The CP-treated group showed significant decreases in the body, testes and epididymis weights and sperm parameters [sperm count, viability, motility] with an increase abnormal sperms when compared with the control [p<0.001], as well as many histological alterations included decreased diameters of seminiferous tubules and Johnsen's Testicular Score [with degeneration, desquamation, multi-nucleated giant cell formation], whereas combined treatment [GV], showed more protective effects on CP-induced reproductive system damage compared with groups III or IV [p<0.001]

Conclusion: These results suggest simultaneous administration of Mel and nZno have more effectively protections against CP-induced reproductive damage than Mel or nZno alone

Evaluation of the genotoxicity and mutagenicity of Ca3SiO5-based cement

Abstract Ca3SiO5 is new cement based on the composition of Portland that has been developed to have superior physicochemical and biological properties. In a clinical evaluation, the cement did not appear to have cytotoxic properties and allowed for the proliferation of pulp cells and gingival fibroblasts. However, no previous studies have evaluated the genotoxicity or the mutagenicity of Ca3SiO5in vivo. Therefore, the goal of this study is to evaluate the genotoxic and mutagenic potential of Ca3SiO5-based cement in vivo. Twenty-four male Wistar rats were divided into 3 groups (n = 8). Group A rats received subcutaneous implantation of Ca3SiO5 in the dorsum. Group B rats received a single dose of cyclophosphamide (positive control). Group C rats received subcutaneous implantation of empty tubes in the dorsum (negative control). After 24 hours, all animals were euthanized and the bone marrow of the femurs was collected for use in the comet assay and the micronucleus test. The comet assay revealed that the Ca3SiO5 group had a tail intensity of 23.57 ± 7.70%, the cyclophosphamide group had a tail intensity of 27.43 ± 7.40%, and the negative control group had a tail intensity of 24.75 ± 5.55%. The average number of micronuclei was 6.25 (standard deviation, SD = 3.53) in the Ca3SiO5 group, 9.75 (SD = 2.49) in the cyclophosphamide group, and 0.75 (SD = 1.03) in the negative control group. There was an increase in the micronuclei frequency in the Ca3SiO5 group compared to that of the negative control group (p < 0.05). Our data showed that exposure to the Ca3SiO5-based cement resulted in an increase in the frequency of micronuclei, but no genotoxicity was detected according to the comet assay.

Análisis fitoquímico de Jatropha dioica y determinación de su efectoantioxidante y quimioprotector sobre el potencial genotóxico deciclofosfamida, daunorrubicina y metilmetanosulfonato evaluadomediante el ensayo cometa / Phytochemical analysis of Jatropha dioica and determination of its antioxidant and chemopreventive effect on the genotoxic potential of cyclophosphamide, daunorubicin and methyl methane-sulfonate evaluated by the comet assay

Dragon ́s blood root (Jatropha dioica) underwent a phytochemical screening showing the presence of flavonoids and terpenes responsible for the antioxidant potential observed in DPPH model for the decoction, aqueous and methanolic extracts. The chemoprotective effect of the root decoction was evaluated in liver, kidney and bone marrow cells of mice using the comet assay. Mutagens were administered via IP: cyclophosphamide (CCF) 50 mg/kg, daunorubicin (DAU) 10 mg/kg, and metyl metanesulfonate (MMS) 40 mg/kg, were co-administered with three doses of decoction 3.72 ml/kg, 10.71 ml/kg, and 21.42 ml/kg orally. Animals were sacrificed at 3, 9, 15 and 21 h after inoculation. The chemoprotective effect decreased DNA breaks at 3 hours in all organs, and longer against CCF and DAU, this effect probably being related to the antioxidant capacity of the decoction.

La raíz de Sangre de Drago (Jatropha dioica) se sometió a un tamizaje fitoquímico destacando la presencia de flavonoides y terpenos, posibles responsables del efecto antioxidante observado en el modelo de DPPH para la decocción, extracto acuoso y metanólico de la raíz. El efecto quimioprotector de la decocción, se evaluó en células hepáticas, renales y de médula ósea de ratón, mediante el ensayo cometa. Los mutágenos administrados vía I.P.: ciclofosfamida (CCF) 50 mg/kg, daunorrubicina (DAU) 10 mg/kg y metilmetanosulfonato (MMS) 40 mg/kg, se co-administraron con tres dosis de decocción 3,72 ml/kg, 10,71 ml/kg y 21,42 ml/kg, vía oral. Los animales fueron sacrificados a las 3, 9, 15 y 21 h posteriores a la aplicación. El efecto quimioprotector disminuyó las rupturas del DNA a las 3 horas en todos los órganos con los tres mutágenos, y permaneció por más tiempo frente a CCF y DAU, dicho efecto está relacionado con la capacidad antioxidante de la decocción.

Comparación entre dos biomodelos murinos (ratones Balb/c y ratas Sprague Dawley) en el ensayo de micronúcleos transplacentarios / Comparison between two murine biomodles (Balb/c mice and Sprague Dawley rats) in a transplacental micronucleus assay

Objetivo: comparar fetos de ratones Balb/c y ratas Sprague Dawley como biomodelos en el ensayo de micronúcleos transplacentarios, determinando la frecuencia espontánea e inducida, y vincular el efecto genotóxico y reproductivo. Métodos: se formaron tres grupos experimentales/especie: control negativo (simulacro), control solvente NaCl (0,9 %) y ciclofosfamida 50 mg/kg. Todos los grupos se administraron por vía intraperitoneal los días 14, 15 y 16 de la gestación, y 24 h después de la última inoculación en ratones y 48 h en ratas se procedió a realizar la eutanasia de las gestantes, para obtener las muestras de hígado fetal. Resultados: los fetos de ratas Sprague Dawley demostraron tener menores índices de citotoxicidad y de genotoxicidad, y se obtuvieron los resultados más bajos de micronúcleos endógenos. Los mejores resultados de inducción de citotoxicidad y genotoxicidad por la alta formación de micronúcleos con ciclofosfamida fueron en fetos de ratas Sprague Dawley, los que resultaron más susceptibles al daño genotóxico de este mutágeno. Se corroboró el poder clastogénico transplacentario de la ciclofosfamida, vinculando este ensayo de genotoxicidad a toxicología de la reproducción. Conclusiones: los resultados sugieren el mejor uso de fetos de ratas Sprague Dawley como biomodelo en este ensayo cuando es utilizada la ciclofosfamida como control positivo por la vía y dosis estudiada; además, se pudieran utilizar en la evaluación de nuevas drogas con carácter antigenotóxico por vía transplacentaria.

Objectives: to compare fetuses from Balb/c mice and Sprague Dawley rats as biomodels in transplacental micronuclei assay and to determine the spontaneous and induced frequency to link the genotoxic and reproductive effect. Methods: three experimental groups by species were formed: a negative control (simulation), NaCl (0.9 %) solvent control and 50 mg/kg cyclophosphamide. All the groups were intraperitoneally administered at 14th, 15th and 16th days of gestation, and 24 h after the last inoculation in mice and 48 h in rats, it proceeded to perform euthanasia in the pregnant animals to obtain the fetal liver samples. Results: the fetuses from Sprague Dawley exhibited smaller cytotoxicity and genotoxicity indexes, and the lowest endogenous micronucleus results. The best results of the cytotoxicity and genotoxicity induction for the high micronucleus formation with cyclophosphamide were found in Sprague Dawley rat fetuses, being more susceptible to the genotoxic damage by this mutagen. The clastogenic transplacental power of cyclophosphamide was confirmed whereas this genotoxicity assay was linked to reproduction toxicology. Conclusions: these results suggest that the Sprague Dawley rats fetuses could be better used as biomodels in this assay when cyclophosphamide is employed as positive control through the way of administration and the studied dosage. It could be similarly used in the evaluation of new antigenotoxic drugs with antigenotoxic effect through transplacental administration.

Crataegus monogyna aqueous extract ameliorates cyclophosphamide-induced toxicity in rat testis: stereological evidences

Cyclophosphamide [CP] is extensively used as an antineoplastic agent for the treatment of various cancers, as well as an immunosuppressive agent. However, despite its wide spectrum of clinical uses, CP is known to cause several adverse effects including reproductive toxicity. Crataegus monogyna is one of the oldest pharmaceutical plants that have been shown to be cytoprotective by scavenging free radicals. The present study was conducted to assess whether Crataegus monogyna fruits aqueous extract with anti-oxidant properties, could serve as a protective agent against reproductive toxicity during CP treatment in a rat model. Male Wistar rats were categorized into four groups. Two groups of rats were administered CP at a dose of 5 mg in 5 ml saline/kg/day for 28 days by oral gavages. One of these groups received Crataegus monogyna aqueous extract at a dose of 20 mg/kg/day orally four hours after cyclophosphamide administration. A vehicle treated control group and a Crataegus monogyna control group were also included. The CP-treated group showed significant decreases in the body, testes and epididymides weights as well as many histological alterations. Stereological parameters and spermatogenic activities [Sertoli cell, repopulation and miotic indices] were also significantly decreased by CP treatment. Notably, Crataegus coadministration caused a partial recovery in above-mentined parameters. These findings indicate that Crataegus monogyna may be partially protective against CP-induced testicular toxicity

Toxic effects of different doses of cyclophosphamide on the reproductive parameters of male mice / Os efeitos tóxicos de diferentes doses de ciclofosfamida nos parâmetros reprodutivos de camundongos machos

The cyclophosphamide is used in cancer treatment. The aim of this study was evaluating the effect of different doses of this drug on male mice reproductive parameters. The cyclophosphamide was administered in the doses 100, 150, 200 e 250 mg.kg-1, intraperitoneal route, for six weeks. As a result, it was observed a decrease in body mass and a decrease in testicles and kidney's weight, in all animals treated with cyclophosphamide. Only the groups that received the doses 100, 150 mg.kg-1 of cyclophosphamide were able to fertilize their females. There was higher incidence of post- implantation losses, reabsorptions and decrease in fetal viability in the group that received the dose of 150 mg.kg-1. It was observed a reduction in epididymis and liver's weight of the animals treated with the doses 150, 200 e 250 mg.kg-1. Abnormal spermatozoa were found in the doses 200 e 250 mg.kg-1. Based on the methodology used and results obtained, it was concluded that the cyclophosphamide was toxic, considering the decrease in animal's body mass and testicle's weight; promoted hepatotoxicity and nephrotoxic effect; influenced in the animals spermatogenesis taking them to infertility and/or subfertility; decreased fetal viability, despite it didn't cause significant malformations in the offspring.

A ciclofosfamida é utilizada no tratamento de câncer. Este estudo visa avaliar os efeitos das diferentes doses do fármaco nos parâmetros reprodutivos de camundongos machos. A ciclofosfamida foi administrada nas doses de 100, 150, 200 e 250 mg kg-1, via intraperitoneal por seis semanas. Como resultado observou-se diminuição de massa corporal, redução no peso de testículos e rins em todos os animais tratados com a ciclofosfamida. Apenas os grupos que receberam as doses de 100 e 150 mg kg-1 do quimioterápico foram capazes de fertilizar as fêmeas. Houve maior incidência de perdas pós-implantação, reabsorção e diminuição da viabilidade fetal no grupo que recebeu a dose de 150 mg kg-1. Observou-se redução nos pesos dos epidídimos e fígado dos animais tratados com as doses de 150, 200 e 250 mg kg-1. Espermatozóides anômalos foram encontrados nas doses de 200 e 250mg kg-1. Com base na metodologia empregada e nos resultados obtidos, conclui-se que a ciclofosfamida foi tóxica considerando-se a redução de massa corporal e o peso dos testículos dos animais; promoveu hepatotoxicidade e efeito nefrotóxico; influenciou na espermatogênese dos animais de forma a levá-los a um estado de infertilidade e/ou subfertilidade; diminuiu viabilidade fetal, entretanto não causou malformações significativas na prole.

Expressions of Uroplakins in the Mouse Urinary Bladder with Cyclophosphamide-Induced Cystitis

Even though uroplakins (UPs) are believed to serve a strong protective barrier against toxic materials, cyclophosphamide (CP) causes extensive cystitis. We investigated the expression of UPs in the urothelium in CP induced mouse cystitis. A total of 27 ICR female mice received a single intraperitoneal injection of 200 mg CP/kg. Nine CP-treated mice and 6 controls were sequentially killed at 12, 24, and 72 hr post injection. Extensive cystitis and an increased vesical weight were seen. These all peaked within 12 hr post injection and they tended to decrease thereafter. The level of all the UPs mRNA, the protein expressions of UP II and III on immunoblotting study, and the expression of UP III on immunolocalization study were maximally suppressed within 12 hr; this partially recovered at 24 hr, and this completely recovered at 72 hr post CP injection. In conclusion, CP reduced the expression of UPs. The reduction of the UPs mRNA and protein was time dependent, and this peaked within 12 hr after CP injection. However, the damage was rapidly repaired within 24 hr. This study demonstrates a dynamic process, an extensive reduction and rapid recovery, for the UPs expression of the mouse urinary bladder after CP injection.

Absence of antimutagenicity of Cochlospermum regium (Mart. and Schr.) Pilger 1924 by micronucleus test in mice

Cochlospermum regium (Mart. and Schr.) Pilger, popularly known as "algodãozinho do campo", is a medicinal plant that grows in the Cerrado of Brazil. This plant has been used in traditional medicine against various diseases such as leucorrhoea, gastritis and ulcers. It has also been effective in treating skin problems like pimples, boils and blotches. In the present study, the in vivo antimutagenicity of aqueous extract of C. regium was evaluated. The Micronucleus Test was performed in polychromatic erythrocytes from Swiss male mice treated with one of the four doses of extract of the plant (19, 38, 76 and 114 mg.kg-1 body weight), administered by intraperitonial injection (i.p.) simultaneously with cyclophosphamide (24 mg.kg-1 b.w.) or mitomycin C (4 mg.kg-1 b.w.). The cytotoxicity was evaluated by polychromatic and normochromatic erythrocytes ratio (PCE/NCE). The results showed no significant reduction of the micronucleated polychromatic erythrocytes frequency (P > 0.05). In conclusion, the data indicate that C. regium roots aqueous extract, for the conditions used, did not exhibit the antimutagenic effect.

Cochlospermum regium (Mart. & Schr.) Pilger, conhecido popularmente como "algodãozinho-do-campo", é uma planta medicinal que cresce no Cerrado brasileiro. Esta planta tem sido utilizada na medicina tradicional contra várias doenças como leucorréia, gastrites e úlceras. Esta também tem se mostrado efetiva no tratamento de doenças de pele como espinhas, furúnculos e manchas. No presente estudo, foi avaliada a antimutagenicidade do extrato aquoso de C. regium pelo Teste do Micronúcleo in vivo. Este ensaio foi realizado em eritrócitos policromáticos de camundongos machos Swiss tratados com quatro concentrações diferentes do extrato da planta (19, 38, 76 e 114 mg.kg-1 por peso corpóreo), administrado por injeção intraperitonial (i.p.) simultaneamente com ciclofosfamida (24 mg.kg-1 p.c.) ou mitomicina C (4 mg.kg-1 p.c.). A citotoxicidade foi avaliada pela razão eritrócitos policromáticos e normocromáticos (PCE/NCE). Os resultados obtidos não mostraram redução significativa da freqüência de eritrócitos policromáticos micronucleados (P > 0,05). Em conclusão, os resultados indicam que o extrato aquoso de raiz de C. regium, para as condições utilizadas, não exibiu efeito antimutagênico.

Fetal Central Nervous System and Thymic Alterations Following Cyclophosphamide Treatment of Pregnant Mice / Alteraciones del Sistema Nervioso Central Fetal y Tunicas Posterior al Tratamiento con Ciclofosfamida en Ratas Preñadas

The present study assessed central nervous system (CNS) and immune system changes in murine fetuses after cyclophosphamide (CP) exposure during intrauterine life. A single CP dose of 0, 10, or 20mg/kg body weight was administered by intraperitoneal inj ection to pregnant mice (20/group) on day 11 of gestation (GD 11) and fetuses were evaluated on day 19 of gestation (GD 19). Fetuses were examined for external changes, and then the brains and thymuses were removed for further evaluations of histological changes, protein content, apoptotic cell count, DNA fragmentation, and in vitro cell proliferation using 1 fetus/litter for each assessment. Brains and thymuses from CP-exposed fetuses were smaller in size and distorted in overall shape compared to those from the control group. Estimated mean protein content (mg/mL) of brains was decreased in the CP-exposed groups. In both brain cells and thymocytes there was an increase in mean apoptotic cell counts and in mean percent DNA fragmentation in the exposed groups. The in vitro cell proliferation assays conducted with cells from exposed fetuses exhibited a mean decrease in the number of both brain cells and thymocytes generated. These findings indicate that maternal CP treatment on GD 11 in mice results in marked fetal toxicity characterized by reduced live litter size, fetal body weights as well as brain and thymic weights and malformations which are accompanied by changes in brain protein content, brain and thymic apoptosis, DNA fragmentation and in vitro cell proliferation at term.

El presente estudio evaluó los cambios en el sistema nervioso e inmunológico en fetos de roedores, luego de exposición a ciclofosfamida (CF) durante la vida intrauterina. Una dosis única de CF de 0, 10, y 20 mg/kg de peso se administró por medio de inyección intraperitoneal en ratas preñadas (grupo de 20) en el día 11 de gestación (DG11) y luego los fetos se evaluaron en el día 19 de gestación (DG19). Fueron examinados los cambios externos de los fetos, y los cerebros y timos se extrajeron para evaluar los cambios histológicos, contenido de proteínas, conteo de células apoptóticas, fragmentación de DNA y proliferación de células in vitro, usando 1 feto por carnada para cada evaluación. Los cerebros y timos de fetos expuestos a CF eran pequeños y completamente deformados , comparado con los del grupo control. La estimación del contenido proteico (mg/mL) de los cerebros estuvo disminuida en los grupos expuestos a CF. En las células del cerebro y timocitos hubo un incremento en el promedio del conteo de células apoptóticas y el porcentaje promedio de la fragmentación de DNA en los grupos expuestos. Los ensayos de proliferación celular in vitro realizados en células de fetos expuestos, mostraron una disminución en el promedio de células cerebrales y timocitos generados. Estos hallazgos indican que el tratamiento materno en el DG11 con CF en ratones significa una marcada toxicidad fetal caracterizada por un reducido tamaño de los nacidos vivos de la carnada, reducidos pesos fetal, cerebral y del timo y malformaciones, las cuales son acompañadas por cambios en el contenido proteico cerebral, apoptosis de células cerebrales y del timo, fragmentación del DNA y proliferación celular in vitro al término.

Antimutagenic effects of piperine on cyclophosphamide-induced chromosome aberrations in rat bone marrow cells.

Piperine is a major pungent substance and active component of black pepper (Piper nigrum Linn.) and long pepper (Piper longum Linn.). Both plants are used worldwide as household spices and condiments. They are also used as important ingredients in folklore medicine in many Asian countries. Therefore, it is of interest to study antimutagenic effects of piperine. In this study, its influence on chromosomes was investigated in rat bone marrow cells. Male Wistar rats were orally administered piperine at the doses of 100, 400 and 800 mg/kg body weight for 24 hours then challenged with cyclophosphamide at a dose of 50 mg/kg body weight by intraperitoneal injection. Twenty-four hours thereafter, all animals were sacrificed and bone marrow samples were collected for chromosomal analysis. The results demonstrated that piperine at a dose of 100 mg/kg body weight gave a statistically significant reduction in cyclophosphamide-induced chromosomal aberrations. In conclusion, piperine may have antimutagenic potential. The underlying molecular mechanisms now require attention.

[Preventive effects of growth hormone on degeneration of rabbit ovarian follicles during cyclophosphamide induced toxicity]

Cyclophosphamide [CP], an antineoplastic drug, is also widely used in treatment of a variety of diseases such as lymphomas, leukemia, neuroblastoma, ovarian carcinoma, breast cancer and auto-immune diseases. However, its use has toxic effects on different tissues of the body, for example, it causes involution and degeneration of ovarian follicles and toxicity in the ovaries. In contrast, growth hormone [GH] improves the function of most body tissues and research has shown that it leads to the increase in the number and size of the ovarian follicles. The purpose of this study was to study the preventive effects of growth hormone during cyclophposphamide induced toxicity on the ovarian follicles. In this study, 30 New Zealand white rabbits were divided into three groups containing 10 animals in each. Group 1 was the control group and only received placebo. Groups 2 and 3 were administrated 100 mg/kg body weight CP orally daily. Group 3 was also administered growth hormone 0/15 mg/Kg subcutaneously for 49 days [from 7 days before initiation of CP therapy to 14 days after the last administration of CP].The day after last administration of CP, all 30 rabbits were anesthetized by ether and ovariectomized and the number of different types of developing follicles, regressive follicles and degenerations in ovarian tissue was studied. Degeneration of follicles was observed in both groups 2 and 3, but the number of degenerated follicles in group two was more than that in group 3 which had received GH. The number of degenerated areas in ovarian tissue in group 2 was also higher than that in the other two groups. The difference between body weight and the weight of the ovaries in groups 1 and 3 was not significant, but there was a significant decrease in body weight and ovarian These results suggest that co-administration of GH can improve the function of ovary and preserve the ovary and follicles from CP induced toxicity

Comparison of uroprotective efficacy of mesna and amifostine in Cyclophosphamide- induced hemorrhagic cystitis in rats.

BACKGROUND: Hemorrhagic cystitis (HC) is a dose limiting side effect of cyclophosphamide (CYP). AIM: In this study, we aimed to investigate the role of amifostine in the protection of CYP-induced HC and compare its efficacy with mesna. SETTING AND DESIGN: This animal study was conducted in the Experimental Animals Breeding and Research Center of the Medical Faculty of Uludag University. MATERIALS AND METHODS: Male Wistar rats (150-200 g; 10 rats per group) were randomly assigned to four groups. Group I (control group) received no drugs, group II received CYP (200 mg/kg, i.p.) alone, group III received amifostine (200 mg/kg, i.p.) and CYP, and group IV received CYP and mesna (40 mg/kg, i.p.) immediately and 4 and 8 h after administration of CYP. Bladders of animals were assessed macroscopically and histologically 24 h later. Gross assessment for presence of edema and hemorrhage and histological evaluation of damage to the bladder were scored according to Gray's criteria. STATISTICAL ANALYSIS USED: For macroscopic and microscopic data, we used statistical evaluation by Kruskal-Wallis nonparametric analysis of variance followed by the Mann-Whitney U-test. RESULTS: All the animals in group II had evidence of HC. Significant histological damage and macroscopic changes were present in this group compared to control group (P<0.001). The median scores for bladder damage in group III and IV were significantly lower compared to group II (P<0.001). When the median scores for bladder damage of group I, III, and IV were compared, there was no significant difference among these groups. CONCLUSION: This study demonstrated the efficacy of amifostine in prevention of cyclophosphamide-induced hemorrhagic cystitis.

Construction and application of a yeast expression system for thymosin a1

We want to construct a yeast expression system for thymosin a1 (Ta1) to make the orally administered Ta1 preparation possible. The whole Ta1 DNA fragment was obtained by PCR. After being digested with restriction enzymes, it was cloned into pYES2 vector. Sequencing was performed to identify the recombinant. The sequence of Ta1 in recombinant coincided with the original one reported in Genbank. When pYES2-Ta1 plasmid was transformed into yeast, galactose instead of glucose was used to induce Ta1 expression. Western blot was performed to identify the quality of the expressed Ta1. Dried yeast containing pYEST2-Ta1 was fed to Balb/c mice whose immunities were inhibited by cyclophosphamide in advance. Synthesized Ta1 peptide was used as positive control and empty yeast was used as negative control. Compared with the negative control group, both dried yeast containing pYEST2-Ta1 and synthesized Ta1 peptide can significantly increase the CD8+ level (22.74±1.09 and 18.77±4.72 vs 7.49±2.14, p<0.01), while both of them had little effect on the CD4+ lymphocytes (61.86±6.94 and 65.91±4.78 vs 57.93±10.40, p>0.05). We concluded that a high effective yeast expression system for Ta1 was constructed successfully and the Ta1 protein expressed by this system can improve CD8+ level in immune inhibited mice.

CMF with or without medical castration in pre-menopausal women with node positive breast cancer

The prognosis of breast cancer in young women is generally considered to be unfavorable. Thus adjuvant therapy post surgical intervention is essential in many patients especially those with high risk [e.g large tumors or positive nodes]. However the presence of steroid hormone receptors in the primary tumors of young ladies may represent a suitable target for therapy in this group of patients. In the current study 100 premenopausal women with positive axillary lymph nodes and have estrogen and/or progestrone receptor positive tumors were randomized after local therapy of the breast cancer into two groups; Group I received adjuvant chemotherapy CMF for a total of six cycles then medical castration with LHRH agonist for two years and Group II received the same chemotherapy as in group I for six cycles. Adjuvant radiotherapy was given in the majority of patients in both treatment groups. After median follow up of six years, there was no statistical significance difference between both groups as regard the disease free or overall survival P=0.537 and 0.526 respectively. The toxicity reported in both groups was quite mild with only increase in the rate of hot flashes in the medical castration group. This study confirm the safety and tolerability of addition of medical castration to adjuvant chemotherapy which can be easily accepted by young women because of its reversible action, however it didn't answer many important questions about the optimum duration of ovarian suppression and the need for combined hormonal therapy like addition of tamoxifen to ovarian castration and sequence of different therapy

Docetaxel, doxorubicin and cyclophosphamide [TAC] as first line-chemotherapy for metastatic breast cancer

This study was designed to investigate the efficacy and toxicity of docetaxel with doxorubicin and cyclophosphamide [TAC] as first-line chemotherapy for metastatic breast cancer. Forty-four patients received 3-week cycles of docetaxel 75 mg/m[2] 1 hour I. V. infusion, preceded by I. V. doxorubicin 50 mg/m[2] and cyclophosphamide 500 mg/m[2] for a maximum of 6 cycles. Complete response was achieved in 4 patients [9%]. The overall objective response rate was 70%. The objective response rates in patients with bone, lymph nodes, liver and lung involvement was 81%, 73%, 71% and 67% respectively. The median duration of response was 12 months and the median time to progression was nine months. With a median follow-up of 18 months, the median survival was 18 months whereas the 1 and 2-year survival rates were 64% and 38% respectively. The main toxicities were hematological [neutropenia in 82% of patients, anemia in 46% and thrombocytopenia in 25% of patients]. Non-hematological adverse events were infrequent and docetaxel-specific toxicities [such as fluid retention and nail changes] were mild. No anaphylaxis, cardiac toxicity or febrile neutropenia were observed in any patient. The docetaxel-doxorubicin-based TAC combination seems to be active as first-line treatment of patients with metastatic breast cancer. Although neutropenia was frequent, it was manageable. The rest of the toxicity profile seems acceptable, with no significant nonhematologic toxicities. Further randomized trials are needed to establish the role of docetaxel in the treatment strategies and natural history of breast cancer

Antimutagenic effects of black tea in the Salmonella typhimurium reverse mutation assay.

Black tea (Camellia sinensis) is one of the most widely consumed beverages worldwide. Its chemopreventive effects are well documented in the literature. In the present set of investigations antimutagenic effects of aqueous black tea extract (ATE) and black tea polyphenols (BTP) were evaluated in the Ames test using Salmonella typhimurium tester strains TA 98 and TA 100. Addition of benzo(a)pyrene (BaP) and cyclophosphamide (CP), two well known mutagens, at the concentrations of 20 and 15 microg/plate, respectively, in an S-9 metabolically activated system resulted in significant induction of his+ revertant colonies. However, addition of 500 microl 1, 2 and 4% ATE to the BaP and CP treated plates resulted in a dose dependent inhibition in the number of his+ revertant colonies. Furthermore in another set of experiments, supplementation with BTP at the concentrations of 100, 200 and 400 microg/plate also led to a significant inhibition in BaP and CP induced colony formation. The antimutagenic activity of BTP was found to be higher than that of ATE, which may be attributable to the higher amount of polyphenolic ingredients. Hence the study revealed that black tea has a protective efficacy in suppressing BaP and CP induced mutagenicity in a microbial test system.

Efficiency of Coleus aromaticus extract in modifying cyclophosphamide and mitomycin-C induced clastogenicity in mouse bone marrow cells.

The anticlastogenic potency of the ethanolic extract of a medicinal plant, C. aromaticus was investigated by taking bone marrow chromosomal aberration assay and micronucleus (MN) test as the test parameters. Swiss albino mice were fed orally with different doses (10,15, 25, 50 and 100 mg/kg body weight) of ethanolic extract for 7 days and on the 7th day, two doses each of anticancer drugs cyclophosphamide (CP; 25 and 50 mg/kg body weight) and mitomycin-C (MMC; 4 and 8 mg/kg body weight) were injected, ip, to different groups of animals. Bone marrow MN preparations were made at 24 and 48 hr time intervals. Coleus extract reduced CP and MMC induced MN and lower doses of the extract were found to be more effective than higher doses. The effective doses of extract in MN test were selected to study the anticlastogenic effects against CP (25 and 50 mg/kg body weight) and MMC (2 and 4 mg/kg body weight) induced chromosomal aberrations. The results indicate the protective effect of C. aromaticus against CP and MMC induced cytogenetic damage.

Evaluación de la genotoxicidad de ciclofosfamida mediante prueba de micronúcleos en pacientes con lupus eritematoso sistémico / Assessment by micronuclei assay of genotoxicity by cyclophosphamide in systemic lupus erythematosus patients

Los pacientes con lupus eritematoso sistémico (LES) tienen un mayor riesgo para desarrollar cáncer. La ciclofosfamida (CFA) representa también un riesgo para desarrollar cáncer a largo plazo. Este medicamento se utiliza en pacientes con LES. La prueba de micronúcleos (MN) se ha utilizado para valorar genotoxicidad. No se ha estudiado si el uso de este fármaco en pacientes con LES induce MN.Objetivos: Evaluar si los pacientes con LES tratados con ciclofosfamida (CFA) tienen más micronúcleos que los controles sanos. Pacientes y Métodos: Se estudiaron pacientes con LES que estuvieran manejados con bolos mensuales de CFA. Los pacientes fueron evaluados por un cuestionario estructurado para variables demográficas y clínicas. Se determinaron MN en 4 ocasiones diferentes mediante raspado de mucosa oral; la primera toma fue inmediatamente antes del bolo, la segunda a los 14 días, la tercera inmediatamente antes del siguiente bolo y la última 14 días después. Cuarenta y tres voluntarios sanos sirvieron como controles. Un técnico cegado a datos demográficos de los pacientes cuantificó los MN. Resultados: Se incluyeron 10 pacientes; todos fueron mujeres; el promedio de edad fue de 38 ñ 8 años y el de la duración de la enfermedad de 9 ñ 5 años. El promedio de SLEDAI-MEX al inicio del estudio fue de 7.1 ñ 3.5. Se hicieron 34 determinaciones de MN en 10 pacientes (7 pacientes con 4 determinaciones, 3 pacientes con 2 determinaciones). El promedio global de MN en las pacientes con LES fue de 3.6 ñ 1.3 y de los controles de 1.3 ñ 1.3 (p=0.001). El número de MN fue mayor a los 14 días en comparación con las determinaciones antes de la administración del bolo. Conclusión: El número de MN en pacientes con LES tratados con CFA es mayor que en controles sanos, lo que refleja daño citogenético. Los resultados sugieren que el incremento de MN es mayor 14 días después de la exposición a la CFA. Serán necesarios estudios con mayor número de pacientes y seguimiento a largo plazo para determinar el riesgo que representan los MN para el desarrollo de cáncer.

Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna

Chemotherapy with oxazaphosphorines, such as cyclophosphamide (CYP), is often limited by unacceptable urotoxicity. Without uroprotection, hemorrhagic cystitis (HC) becomes dose-limiting. To compare the uroprotective efficacy of classical 2-mercaptoethanesulfonic acid (Mesna) treatment with dexamethasone in CYP-induced HC, male Wistar rats (150-200 g; N = 6 in each group) were treated with saline or Mesna (40 mg/kg, ip) immediately and 4 and 8 h after ip administration of CYP (200 mg/kg). One, 2 or 3 doses of Mesna were replaced with dexamethasone (1 mg/kg, ip). The animals were sacrificed 24 h later. Cystitis was evaluated by determining the changes in bladder wet weight (BWW) and by macroscopic and microscopic analysis. CYP treatment induced a marked increased in BWW 162 percent 0.05, which was significantly inhibited by treatment with 3 doses of Mesna 0.05; 80 percent. The replacement of 1 or 2 doses of Mesna with dexamethasone reduced the increase in BWW by 83.3 and 95 percent, respectively. Macroscopic analysis of the bladder of rats with CYP-induced HC showed severe edema and hemorrhage, confirmed by microscopic analysis, that also showed mucosal erosion, inflammatory cell infiltration and ulcerations. The replacement of 1 or 2 doses of Mesna with dexamethasone inhibited the CYP-induced increase in BWW and almost abolished the macroscopic and microscopic alterations, with no significant difference between the effects of Mesna and dexamethasone, indicating that both drugs were efficient in blocking HC. However, although the replacement of all Mesna doses with dexamethasone reduced the edema, it did not prevent HC, suggesting that Mesna is necessary for the initial uroprotection